Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China

from Quality of Life Research at http://bit.ly/2FbwNi7 on February 28, 2018 at 08:36PM Abstract Purpose To investigate the validity of direct and indirect health state utility (HSU) and subjective well-being measures in psoriasis vulgaris patients. Methods A convenience sampling framework was used to successively recruit patients with psoriasis vulgaris from the outpatient clinics of a […]

A 2-Day Workshop by Professor Charles Manski at McMaster

from CCHE General Updates Archive Feed at http://bit.ly/2oC7Web on February 28, 2018 at 07:19PM Personalizing Patient Care Under Uncertainty:Techniques to Inform Development of Clinical Guidelines and Treatment Choice Canadian Centre for Health Economics View this email in your browser Personalizing Patient Care Under Uncertainty: Techniques to Inform Development of Clinical Guidelines and Treatment Choice A […]

Everyone Agrees Obamacare Prices Have Been Rising Rapidly (But Everyone Is Wrong)

from PeterUbel.com at http://bit.ly/2oDj4qk on February 28, 2018 at 02:02PM (Photo by Joe Raedle/Getty Images) It has been well publicized that premiums for Obamacare insurance plans have been rising at a disturbing rate. Local news is filled with reports of 21.5%, 36.3% and even higher price hikes. President Trump complained in February that Obamacare premiums “have increased by double and triple […]

NPC’s Dubois Talks Tradeoffs in Health Resource Allocation

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2F9Upnf on February 27, 2018 at 06:28PM Robert Dubois, National Pharmaceutical Council chief science officer and executive vice president, recently spoke on some of the trade-offs involved with allocation of health care resources. Dubois in his comments drew a parallel to the movie Groundhog Day, such that some […]

Report: ‘Pharma Must Seek Alternative Pricing Models’

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2CpGR6m on February 27, 2018 at 05:58PM Pricing models must evolve in tandem with drug innovation, according to an article published on eyeforpharma. However, in a “cash-strapped healthcare system,” the difficulty in developing and implementing innovative payment models is a “mountainous challenge.” Numerous companies are reportedly taking up […]

NPC Launches New Research Initiative

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2CMWdxw on February 27, 2018 at 05:28PM The National Pharmaceutical Council has launched a new research initiative, dubbed Going Below the Surface, aimed at analyzing the drivers of U.S. health care spending. “The goal is to provide clarity on how we can optimize our health spending while simultaneously […]

Health-promoting behaviors benefit the mental health of cirrhotic outpatients

from Quality of Life Research at http://bit.ly/2BWKVdo on February 27, 2018 at 04:36PM Abstract Purpose The objectives of this study were to survey the frequency of engaging in a health-promoting lifestyle in patients with liver cirrhosis, and examine the mediating effects of a health-promoting lifestyle on relationships of symptoms and psychological distress with the quality […]

New Study Shows Most Women Willing to Accept the Risks of Breast Screening

from ISPOR News & Press Releases at http://bit.ly/2CmcBco on February 27, 2018 at 12:17PM Value in Health Report Quantifies Women’s Preferences Lawrenceville, NJ, USA—February 27, 2018—Value in Health, the official journal of ISPOR (the professional society for health economics and outcomes research), announced today the publication of new research suggesting that, on average, most women […]

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer

from PharmacoEconomics at http://bit.ly/2EWPwe3 on February 27, 2018 at 09:30AM Abstract Background The recently completed ALEX trial demonstrated that alectinib improved progression-free survival, and delayed time to central nervous system progression compared with crizotinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. However, the long-term clinical and economic impact of using alectinib vs. crizotinib […]

Veteran status, disability rating, and public sector employment

from Health Economics at http://bit.ly/2oyjbTK on February 27, 2018 at 09:06AM Abstract This paper used microdata from the 2013–2015 American Community Survey to examine differences in federal government, state and local government, private sector, and self-employment among employed veterans and nonveterans. The U.S. federal and state governments have hiring preferences to benefit veterans, especially disabled […]

HEDS Short Course – An introduction to using Social Media to Communicate Research

from Health Economics and Decision Science Blog @ ScHARR at http://bit.ly/2Csdy30 on February 27, 2018 at 08:30AM HEDS are running a one day course An introduction to using Social Media to Communicate Research on Tuesday 15th May at Halifax Hall in Sheffield. Background: The treadmill of academia is a relentless one: proposal, research, write, present […]

Q-TWiST: One approach for measuring quality-adjust survival gains in cancer

from Healthcare Economist at http://bit.ly/2HQTfvI on February 27, 2018 at 07:57AM Defining which cancer treatments are the “best” is not as easy as you think.  At first glance, treatments that produce the largest survival gains should be considered best.  Most cancer treatments come with serious side effects.  Thus, new treatments that better improve survival may […]

Agreement between retrospectively and contemporaneously collected patient-reported outcome measures (PROMs) in hip and knee replacement patients

from Quality of Life Research at http://bit.ly/2Fw03Ol on February 26, 2018 at 09:36PM Abstract Purpose To investigate the relationship between retrospectively and contemporaneously collected patient-reported outcome measures (PROMs) and the influence on this relationship of patients’ age and socio-economic status and the length of time. Methods Patients undergoing hip or knee replacement in four hospitals […]

ISPOR Special Task Force Report Focuses on Range of Issues

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2GMWEdz on February 26, 2018 at 05:46PM The International Society for Pharmacoeconomics and Outcomes Research’s latest Value in Health contains several reports from the society’s Special Task Force on U.S. Value Assessment Frameworks. According to a press release, the publications, which appear in a themed section of Value […]

Changing the Payer Mindset

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2BR9Oa9 on February 26, 2018 at 04:46PM A move by the Center for Medicare and Medicaid Services toward value-based contracting could have a powerful impact on the payer market. A recent write up published on Lexology takes a look at the CMS Center for Medicare and Medicaid Innovation, […]

National Drug Policy Face-off: Some Notes Justifying the Regulations and Drug Price Control Regime in India

from Health Economics at http://bit.ly/2HQ5too on February 26, 2018 at 04:42PM This is an attempt in examining and carrying out the discussion and debate on regulations and prince control in pharmaceutical industry in the Indian context. Herein the above discussion presented the perspectives of the industry and the welfare of the poor population along with […]